{"slug":"tirzepatide-muscle-loss","verification":{"valid":true,"entries":2,"head":"be3ec4612f3cc48287cd347e9d843b2f01220de888b5697a5147e8f03fd2858b"},"energy":{"passes":2,"tokens_in":20535,"tokens_out":2677,"tokens_total":23212,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"be3ec4612f3cc48287cd347e9d843b2f01220de888b5697a5147e8f03fd2858b"},"provenance":[{"ts":"2026-06-29T22:45:59.086Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tirzepatide for Muscle Loss\nSlug: tirzepatide-muscle-loss\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\",\"**What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\",\"**Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your conditio","response":"{\n  \"slug\": \"tirzepatide-muscle-loss\",\n  \"title\": \"Tirzepatide and Muscle Loss: Human Trial Data on Body Composition\",\n  \"body\": \"## What's breaking down\\nRapid weight loss from caloric deficit often leads to loss of both fat and lean mass, including skeletal muscle. This can occur because the body draws on protein stores when energy intake drops sharply. In people with higher body weight, excess mechanical load on joints and spine compounds degeneration over time, but muscle itself faces catabolic pressure during aggressive fat reduction.\\n\\n## Why Tirzepatide might help you\\n1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight, paired with lean mass reduction during rapid weight drop.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints while producing proportional body composition shifts.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain. Human data show lean mass changes track overall weight loss without disproportionate excess loss beyond placebo proportions.\\n\\n## How these fit together\\nSingle-compound focus — Tirzepatide targets metabolic load / body weight. If your condition profile includes a multi-peptide stack, siblings would target other layers such as direct muscle protein synthesis pathways.\\n\\n## What the evidence actually shows\\nHuman DXA substudy within SURMOUNT-1 (n=160): pooled tirzepatide produced 21.3% total body weight loss vs 5.3% placebo at 72 weeks; fat mass fell 33.9% vs 8.2%; lean mass fell 10.9% vs 2.6%. Of weight lost, ~75% fat and ~25% lean in both arms (human tier). MRI substudy in SURPASS-3 showed muscle volume reduction consistent with expected weight-loss adaptation and greater reduction in muscle fat infiltration than population estimates (human tier). No human trial demonstrates direct cataboli","tokens_in":20535,"tokens_out":2677,"cost":0,"prev":"genesis","hash":"baf11daf4dfef4bf2fe5a02a01191600510fb1ca0a6ed88d7a69b09709c1bf51"},{"ts":"2026-07-17T02:43:17.561Z","model":"owner","action":"voxel_divide","prompt":"","input":"tirzepatide-muscle-loss","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"baf11daf4dfef4bf2fe5a02a01191600510fb1ca0a6ed88d7a69b09709c1bf51","hash":"be3ec4612f3cc48287cd347e9d843b2f01220de888b5697a5147e8f03fd2858b"}]}